Vertex Pharmaceuticals Inc (VRTX)

Price$446.83

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-4.88%

Price vs S&P 500 (4W)3.97%

VGM Score51.01

Market Capitalization$108.72B

P/E Ratio (Annual)27.50x

All Metrics

P/CF (Annual)29.94x

Book Value / Share (Quarterly)$76.17

P/TBV (Annual)6.33x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.35%

Cash Flow / Share (Quarterly)$14.60

Price vs S&P 500 (YTD)-9.60%

Gross Margin (TTM)86.24%

Net Profit Margin (TTM)35.51%

EPS (TTM)$16.87

10-Day Avg Trading Volume1.37M

EPS Excl Extra (TTM)$16.87

Revenue Growth (5Y)14.10%

EPS (Annual)$15.32

ROI (Annual)21.05%

Gross Margin (Annual)86.24%

Net Profit Margin (5Y Avg)26.58%

Cash / Share (Quarterly)$28.51

P/E Basic Excl Extra (TTM)25.06x

Revenue Growth QoQ (YoY)7.82%

EPS Growth (5Y)8.28%

P/E Normalized (Annual)27.50x

ROA (Last FY)15.42%

Revenue Growth TTM (YoY)10.08%

EBITD / Share (TTM)$19.04

ROE (5Y Avg)17.12%

Operating Margin (TTM)38.31%

Cash Flow / Share (Annual)$12.57

P/B Ratio5.61x

P/B Ratio (Quarterly)5.87x

Net Income / Employee (Annual)$617,700

EV / Revenue (TTM)8.30x

Net Interest Coverage (TTM)72.37x

ROA (TTM)17.18%

EPS Growth QoQ (YoY)61.58%

EV / EBITDA (TTM)20.71x

EPS Incl Extra (Annual)$15.32

Current Ratio (Annual)2.90x

Quick Ratio (Quarterly)2.38x

3-Month Avg Trading Volume1.35M

52-Week Price Return0.68%

EV / Free Cash Flow (Annual)31.77x

P/E Incl Extra (TTM)25.06x

Revenue / Employee (TTM)$1,909,100

Tangible BV / Share (Quarterly)$71.82

P/S Ratio (Annual)9.06x

Asset Turnover (Annual)0.47x

52-Week High$507.92

Operating Margin (5Y Avg)31.29%

EPS Excl Extra (Annual)$15.32

CapEx CAGR (5Y)10.99%

Tangible BV CAGR (5Y)17.01%

26-Week Price Return3.05%

Quick Ratio (Annual)2.27x

13-Week Price Return-3.04%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)3.02x

Enterprise Value$101.47B

Revenue / Share Growth (5Y)14.57%

Asset Turnover (TTM)0.48x

Book Value / Share Growth (5Y)17.07%

Revenue / Employee (Annual)$1,875,200

Inventory Turnover (Annual)1.14x

Pretax Margin (Annual)38.69%

Cash / Share (Annual)$26.02

3-Month Return Std Dev29.96%

Gross Margin (5Y Avg)87.10%

Net Income / Employee (TTM)$677,900

EBITDA CAGR (5Y)8.13%

EBITDA Interim CAGR (5Y)5.43%

ROE (Last FY)21.18%

Net Interest Coverage (Annual)16.95x

EPS Basic Excl Extra (Annual)$15.32

P/FCF (TTM)29.30x

Receivables Turnover (TTM)6.43x

EV / Free Cash Flow (TTM)27.35x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$16.87

Receivables Turnover (Annual)6.55x

ROI (TTM)23.89%

P/S Ratio (TTM)8.90x

Pretax Margin (5Y Avg)33.75%

Revenue / Share (Annual)$46.52

Tangible BV / Share (Annual)$71.56

Forward P/E22.27x

Free OCF CAGR (5Y)1.30%

Price vs S&P 500 (52W)-23.69%

P/E Ratio (TTM)25.06x

Year-to-Date Return-1.44%

5-Day Price Return1.92%

EPS Normalized (Annual)$15.32

ROA (5Y Avg)12.94%

Net Profit Margin (Annual)32.94%

Month-to-Date Return-0.16%

Cash Flow / Share (TTM)$13.94

EBITD / Share (Annual)$16.99

EPS Growth (3Y)6.12%

Operating Margin (Annual)34.77%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)25.64x

ROI (5Y Avg)16.60%

P/E Excl Extra (TTM)25.06x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$16.87

P/TBV (Quarterly)6.31x

P/B Ratio (Annual)6.16x

Inventory Turnover (TTM)1.08x

Pretax Margin (TTM)42.28%

Book Value / Share (Annual)$73.49

Price vs S&P 500 (13W)-11.29%

Net Margin Growth (5Y)-5.50%

Beta0.31x

P/FCF (Annual)34.04x

Revenue / Share (TTM)$47.67

ROE (TTM)23.93%

52-Week Low$362.50

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 264.47est. 4.40

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.05

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VRTXVertex Pharmaceuticals Inc	D	C	C	$446.83
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Vertex Pharmaceuticals is a global biotech company with a dominant position in cystic fibrosis treatments (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) and a diversified pipeline including approved gene-editing therapy Casgevy for blood disorders and Journavx for acute pain. The company is also advancing cell therapies for type 1 diabetes and small-molecule programs targeting APOL1-mediated kidney disease.